- Trial phase
- Phase 3 (adult); Phase 2 (infant)
- Time to market
- Vaxcyte plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2028, pending completion of OPUS-2, OPUS-3, and a manufacturing consistency study. Assuming a standard 10-12 month FDA review, potential approval would be in the 2029 timeframe at the earliest.
- Why 6/10
- The next hard, dated catalysts are the OPUS-2 and OPUS-3 Phase 3 topline readouts expected in the first half of 2027 (roughly 4-8 months from now). These are supportive trials for the BLA package, not the primary pivotal study (OPUS-1 already succeeded), so they are less binary. ImpactScore is 6 because VAX-31 is the lead asset driving most of Vaxcyte's value, the catalysts are within ~6-12 months, but the company also has other programs (VAX-24, VAX-A1) and the biggest binary event (OPUS-1) is already past.
Watch for OPUS-2 and OPUS-3 topline data in H1 2027, which will complete the adult Phase 3 package. Positive results would clear the path for BLA submission in H1 2028. The key risk to monitor is whether the serotype 3 and 12F noninferiority nuance versus Capvaxive becomes a regulatory or commercial issue. The stock has already had its primary binary catalyst (OPUS-1), so subsequent readouts are expected to be supportive but less dramatic movers.
Price Chart
Executive Summary
VAX-31 is Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate, the broadest in development, designed to prevent invasive pneumococcal disease and pneumonia by covering 31 bacterial serotypes. In October 2026, the pivotal Phase 3 OPUS-1 trial succeeded against both Pfizer's Prevnar 20 and Merck's Capvaxive, driving a large single-day stock gain. Two more Phase 3 readouts (OPUS-2 and OPUS-3) are due in H1 2027, with a BLA submission planned for H1 2028. The company has $3.4 billion in cash and a Strong Buy analyst consensus, but faces entrenched Big Pharma competition and a multi-year path to commercialization.
How It Works
VAX-31 is a 31-valent pneumococcal conjugate vaccine (PCV) designed to train the immune system to recognize and fight 31 different strains (serotypes) of Streptococcus pneumoniae bacteria. It uses Vaxcyte's carrier-sparing technology to pack more serotypes into a single shot than existing vaccines, aiming to prevent invasive pneumococcal disease (IPD), pneumonia, and ear infections caused by these bacteria.
Trial Status
The pivotal Phase 3 adult trial (OPUS-1) enrolled 4,047 adults aged 50+ and met all prespecified co-primary immunogenicity and safety endpoints in October 2026, demonstrating noninferiority versus both Pfizer's Prevnar 20 (PCV20) and Merck's Capvaxive (PCV21). Two additional Phase 3 trials are ongoing: OPUS-2 (concomitant administration with seasonal flu vaccine) and OPUS-3 (adults previously vaccinated). A Phase 2 infant dose-finding study is also underway.
The Two-Sided Case
Upcoming Catalysts
- OPUS-2 and OPUS-3 Phase 3 topline readouts expected in first half of 2027
- Manufacturing consistency study results (timing TBD, ahead of BLA)
- Phase 2 infant study data readout (timeline not specified)
- BLA submission planned for first half of 2028
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Vaxcyte, Inc. 8-K PCVX ·Originating report